SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 135 filers reported holding SYNDAX PHARMACEUTICALS INC in Q4 2021. The put-call ratio across all filers is 0.21 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $20,248,000 | -20.6% | 1,165,000 | 0.0% | 0.32% | -2.8% |
| Q4 2021 | $25,502,000 | +14.5% | 1,165,000 | 0.0% | 0.33% | +10.9% |
| Q3 2021 | $22,263,000 | +84.6% | 1,165,000 | +65.9% | 0.29% | +81.5% |
| Q2 2021 | $12,059,000 | -73.3% | 702,348 | -65.2% | 0.16% | -75.7% |
| Q1 2021 | $45,100,000 | +4.2% | 2,016,993 | +3.6% | 0.67% | +0.6% |
| Q4 2020 | $43,279,000 | +319.4% | 1,946,000 | +178.3% | 0.66% | +228.7% |
| Q3 2020 | $10,320,000 | +41.4% | 699,200 | +42.0% | 0.20% | +27.0% |
| Q2 2020 | $7,299,000 | +193.5% | 492,500 | +117.3% | 0.16% | +96.3% |
| Q1 2020 | $2,487,000 | -5.5% | 226,680 | +0.7% | 0.08% | -45.6% |
| Q3 2017 | $2,633,000 | -16.2% | 225,000 | 0.0% | 0.15% | -24.0% |
| Q2 2017 | $3,143,000 | – | 225,000 | – | 0.20% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 1,025,000 | $21,648,000 | 10.42% |
| Foresite Capital Management IV, LLC | 875,000 | $18,480,000 | 9.59% |
| Kynam Capital Management, LP | 3,205,986 | $67,710,424 | 8.74% |
| Frazier Life Sciences Management, L.P. | 3,708,838 | $78,330,659 | 5.67% |
| ACUTA CAPITAL PARTNERS, LLC | 330,000 | $6,969,600 | 5.13% |
| Paradigm Biocapital Advisors LP | 2,274,512 | $48,037,693 | 4.55% |
| Eversept Partners, LP | 2,209,057 | $46,655,284 | 3.25% |
| DAFNA Capital Management LLC | 447,073 | $9,442,182 | 2.83% |
| COMMODORE CAPITAL LP | 853,884 | $18,034,030 | 2.75% |
| Avidity Partners Management LP | 3,865,300 | $81,635,136 | 2.71% |